for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

8,505.00GBp

Change

25.00(+0.29%)

Volume

1,394,815

Today's Range

8,413.00

 - 

8,647.00

52 Week Range

5,871.00

 - 

9,335.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
8,480.00
Open
8,430.00
Volume
1,394,815
3M AVG Volume
43.64
Today's High
8,647.00
Today's Low
8,413.00
52 Week High
9,335.00
52 Week Low
5,871.00
Shares Out (MIL)
1,312.27
Market Cap (MIL)
111,325.50
Forward P/E
26.50
Dividend (Yield %)
2.57

Next Event

Q2 2020 AstraZeneca PLC Earnings Release

Latest Developments

More

Fibrogen Says On July 8, Units And Astrazeneca Entered Into An Amendment To Amended And Restated License, Development And Commercialization Agreement

Astrazeneca Says Lynparza Approved In The EU For Pancreatic Cancer

AstraZeneca Says PT010 Significantly Reduced Rate Of Moderate Or Severe COPD Exacerbations In Phase III Ethos Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.26 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.6K
EPS (USD)

2017

4.280

2018

3.460

2019

3.500

2020(E)

4.034
Price To Earnings (TTM)
92.22
Price To Sales (TTM)
5.56
Price To Book (MRQ)
13.02
Price To Cash Flow (TTM)
26.86
Total Debt To Equity (MRQ)
172.35
LT Debt To Equity (MRQ)
149.43
Return on Investment (TTM)
3.54
Return on Equity (TTM)
2.39

Latest News

Latest News

BRIEF-Fibrogen Says On July 8, Units And Astrazeneca Entered Into An Amendment To Amended And Restated License, Development And Commercialization Agreement

* FIBROGEN - ON JULY 8, UNITS AND ASTRAZENECA ENTERED INTO AN AMENDMENT TO AMENDED AND RESTATED LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

Africa could have COVID-19 vaccine in first quarter if human trials work: South Africa trial lead

Africa could have a COVID-19 vaccine in the first quarter of 2021 if human trials underway in South Africa succeed, a university professor heading the trials said on Thursday.

AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer

AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

AstraZeneca-Merck Lynparza wins EU approval for pancreatic cancer

AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

BRIEF-Astrazeneca Says Lynparza Approved In The EU For Pancreatic Cancer

* ASTRAZENECA PLC - LYNPARZA APPROVED IN THE EU FOR PANCREATIC CANCER

FACTBOX-U.S. pours billions into development of coronavirus vaccines, tests

(Updates with BARDA investment in Novavax vaccine, new grants to Regeneron's and AstraZeneca's therapies, updates development stage for AstraZeneca vaccine and diagnostics table) July 7 (Reuters) - As drugmakers race to develop vaccines, tests and therapies for the novel...

BRIEF-AstraZeneca Says Selumetinib Granted Japan Orphan Drug Designation

* ASTRAZENECA PLC - SELUMETINIB GRANTED JAPAN ORPHAN DRUG DESIGNATION Source text for Eikon: Further company coverage:

AstraZeneca, Moderna ahead in COVID-19 vaccine race: WHO

AstraZeneca's <AZN.L> experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday.

Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan

Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan.

Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan

Daiichi Sankyo Co is in discussions with AstraZeneca Plc on developing supplies of a vaccine for the coronavirus in Japan, the Japanese company said on Friday.

Spanish government reaches deal to extend furlough schemes until Sept 30

Spain's government has reached an agreement with unions and the country's main employers' association to extend national furlough schemes, known as ERTEs, by three months until September 30, sources told Reuters on Thursday.

BRIEF-AstraZeneca Says PT010 Significantly Reduced Rate Of Moderate Or Severe COPD Exacerbations In Phase III Ethos Trial

* PT010 SIGNIFICANTLY REDUCED RATE OF MODERATE OR SEVERE COPD EXACERBATIONS IN PHASE III ETHOS TRIAL

BRIEF-AstraZeneca Says Breztri Aerosphere Significantly Reduced Rate Of Moderate Or Severe COPD Exacerbations In Phase III Ethos Trial

* BREZTRI AEROSPHERE SIGNIFICANTLY REDUCED RATE OF MODERATE OR SEVERE COPD EXACERBATIONS IN PHASE III ETHOS TRIAL

AstraZeneca eyes three-drug inhaler opportunity after trial results

AstraZeneca is eyeing the further growth of its respiratory treatments business as a three-drug inhaler was shown to prevent flare-ups and death in cases of smoker's lung.

AstraZeneca taps Scottish firm for 10th COVID-19 vaccine supply deal

AstraZeneca <AZN.L> has signed its tenth supply-and-manufacturing deal for its experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.

AstraZeneca, Scotland's Symbiosis sign deal for COVID-19 vaccine supply

British drugmaker AstraZeneca has signed its tenth supply-and-manufacturing deal for its experimental COVID-19 vaccine with Symbiosis Pharmaceutical for use in clinical trials, the Scottish private firm said on Wednesday.

BRIEF-Symbiosis And Astrazeneca Sign Supply Agreement For Sterile Manufacture Of Covid-19 Vaccine For Clinical Trials

* SYMBIOSIS AND ASTRAZENECA SIGN SUPPLY AGREEMENT FOR STERILE MANUFACTURE OF COVID-19 VACCINE FOR CLINICAL TRIALS

Pig trial of AstraZeneca's COVID-19 vaccine shows promise with two shots

A trial in pigs of AstraZeneca's <AZN.L> experimental COVID-19 vaccine has found that two doses of the shot produced a greater antibody response than a single dose.

BRIEF-Amoy Diagnostics Signs Agreement With AstraZeneca To Promote Co's Diagnostic Kit

* SAYS IT SIGNS AGREEMENT WITH ASTRAZENECA TO PROMOTE CO'S DIAGNOSTIC KIT Source text in Chinese: https://bit.ly/37Oka8M Further company coverage: (Reporting by Hong Kong newsroom)

Factbox: AstraZeneca's potential coronavirus vaccine

British drugmaker AstraZeneca's latest agreement to manufacture its potential COVID-19 vaccine, with Cobra Biologics, aims for first delivery of the candidate shot to the UK in September.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up